KCA
UTHR icon

KVP Capital Advisors’s United Therapeutics UTHR Stock Holding History

KVP Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.57M Hold
4,750
– – 1.89% 20
2026
Q1 		$2.82M Hold
4,750
– – 2.1% 16
2025
Q4 		$2.31M Buy
+4,750
New +$2.21M 2.24% 16

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

KVP Capital Advisors's UTHR Position: Q2 2026 in Review

KVP Capital Advisors held its United Therapeutics (UTHR) position steady in Q2 2026 at 4,750 shares worth $2.57M. The position accounts for 1.89% of the portfolio, ranked #20.

KVP Capital Advisors first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.82M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • KVP Capital Advisors held 4,750 shares of United Therapeutics worth $2.57M as of Q2 2026.
  • KVP Capital Advisors left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 1.89% of KVP Capital Advisors's portfolio in Q2 2026, its #20 holding.
  • KVP Capital Advisors first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • KVP Capital Advisors's United Therapeutics position peaked at $2.82M in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.